(Photo by Unsplash )
Medication Cures Hepatitis C
WHAT MEDICATION CURES HEPATITIS C ? In the past dual combination therapy of pegylated interferon alfa plus ribavirin was the standard therapy for chronic hepatitis C for many years, this therapy had three serious disadvantages:
The cure rates (SVR rates, SVR = Sustained Virological Response) for genotype 1 were only about 40-50 percent despite a long duration of therapy of six to 18 months. The SVR rate for genotypes 2,3,5 and 6 was significantly higher at 70-90 percent; the SVR rates for genotype 4 were in between.
As part of the therapy, side effects – some of them serious – occurred very often.
Numerous contraindications had to be taken into account, so that a considerable proportion of all patients were not suitable for the therapy. In addition, interferon is contraindicated in decompensated cirrhosis of the liver, so that precisely those patients who needed therapy most urgently could not be treated.
Therapy Who Concepts For Medication Cures Hepatitis C
In recent years, drugs with completely new principles of action have been developed. They intervene directly at different points of the reproduction cycle of the hepatitis C virus and are therefore referred to as direct acting antivirals (DaaS). Depending on the active approach, protease inhibitors, polymerase inhibitors and NS5A inhibitors are distinguished as subgroups.
Currently, eight modern DaaS are approved for the treatment of chronic hepatitis C throughout Europe. The DaaS contain one or more active substances (elbasvir/grazoprevir, daclatasvir, dasabuvir, ombitasvir/paritaprevir/ritonavir, simeprevir, sofosbuvir, sofosbuvir/ledipasvir, sofosbuvir/velpatasvir) and are administered individually or in combination. In addition, the administration of ribavirin or, in some patients, the administration of pegylated interferon alfa may be necessary. All DaaS are taken orally and are characterized by a favorable side effect profile.
Numerous studies have shown that by combining two or three of these new DaaS from different classes, successful therapy of chronic hepatitis C is possible even without interferon. The choice of therapy depends on the genotype and on the stage of liver disease.
The duration of therapy is usually twelve weeks. In some cases, a shortening of therapy to eight weeks or an extension of therapy to up to 24 weeks makes sense. All of the new DaaS mentioned have excellent efficacy against genotype 1. For the other genotypes, the cure rates are slightly lower. Overall, cure rates of around 90 to 95 percent can usually be achieved, even with genotype 3, which is difficult to treat.
Treatment Regimens For Genotype 1 Medication Cures Hepatitis C
Since the modern DaaS mentioned have a high efficacy against genotype 1, there are currently four therapy regimens to choose from for the treatment of this genotype:
Sofosbuvir + Simeprevir
Sofosbuvir + Daclatasvir
Sofosbuvir + Ledipasvir
Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir
Numerous studies have shown that in patients in whom the liver is still functioning well, healing rates of over 95 percent can be achieved with all four therapy regimens with virtually no side effects. However, the combinations sofosbuvir + simeprevir or sofosbuvir + daclatasvir are significantly more expensive than the other two regimens, so they are currently not reimbursed by health insurance providers for genotype 1 therapy in Austria. Therefore, only the other two therapy regimens will be described below.
Sofosbuvir + ledipasvir: the two active substances are combined in one tablet, which must be taken once a day. For patients without cirrhosis of the liver, for whom therapy of chronic hepatitis C has never been carried out, an eight-week therapy is sufficient. All other patients should be treated for twelve weeks.
Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir: Three modern DaaS are combined here. Through the twelve-week administration of this so-called “3D regime”, healing rates of well over 90 percent could be achieved in patients with still good liver function. In some groups of patients (especially in genotype 1a), the additional administration of ribavirin is recommended.
Patients with decompensated cirrhosis of the liver: We speak of decompensated cirrhosis of the liver when the organ can no longer compensate for the decline in function and thus fulfil its tasks. If this is the case, not all modern DaaS can be fully recommended: the two protease inhibitors simeprevir and paritaprevir are broken down in the liver, so that there is a risk that relevant side effects may occur with severely impaired liver function.
In contrast, there are no problems to be feared in this regard with the NS5A inhibitors daclatasvir and ledipasvir and with the polymerase inhibitor sofosbuvir. In patients with decompensated cirrhosis of the liver, the combinations sofosbuvir + ledipasvir and sofosbuvir + daclatasvir have been studied best so far.
Treatment Regimens For Genotype 2 Medication Cures Hepatitis C
In patients with genotype 2, virological cure rates of over 90 percent can be achieved with a twelve-week therapy with sofosbuvir + ribavirin. In patients with cirrhosis of the liver, an extension of therapy to 16 to 20 weeks should be considered. A very good, but more expensive alternative is the combination of sofosbuvir + daclatasvir for twelve weeks.
Treatment Regimens For Genotype 3 Medication Cures Hepatitis C
With the new DAA regimens, genotype 3 is the most difficult genotype to treat. The currently best therapy regimen is the combination of sofosbuvir + daclatasvir: with a twelve-week therapy, virological cure rates of over 95 percent could be achieved in patients without cirrhosis of the liver. For patients with cirrhosis of the liver, however, a longer duration of therapy and /or the additional administration of ribavirin seems to be necessary.
As an alternative to the combination sofosbuvir + daclatasvir, a 24-week therapy with sofosbuvir + ribavirin or a twelve-week therapy with sofosbuvir + ledipasvir + ribavirin can be considered.
Treatment Regimens For Genotype 4 Medication Cures Hepatitis C
Essentially the same treatment regimens are available for genotype 4 as for genotype 1. The most important difference is that in the “3D regimen” dasabuvir is omitted (due to lack of efficacy against genotype 4) and paritaprevir/ritonavir + ombitasvir are combined with ribavirin instead.
Goals Of Therapy Medication Cures Hepatitis C
The goal of therapy is a cure, that is, removal of the hepatitis C virus from the body. One speaks of a cure if no virus is detectable in the blood three months after the end of therapy. As a rule, this is accompanied by a normalization of liver values in the blood, and can also lead to an improvement in the structure of the liver and tissues.
Note Medication Cures Hepatitis C
Successful hepatitis C therapy, as well as a passed infection, does not leave immunity! This means that a new infection with the same genotype or with a different genotype is possible at any time.
Patients in whom HCV reappears in the blood during the first three months after the end of therapy are referred to as relapses. If patients do not respond at all or only very little during therapy and do not achieve virus-free at all, they are referred to as nonresponses. Studies confirm the regenerative capacity of the liver under therapy; this was shown by tissue samples from patients (liver biopsy).
Note Medication Cures Hepatitis C
If you are also taking medications or natural remedies, you should discuss this with your doctor beforehand, as the new medications for the treatment of chronic hepatitis C are not compatible with all medications. During the therapy, laboratory checks are carried out at regular intervals (usually once a month).
What Is The Best Medication For Hep C?
The best medication for Hepatitis C (Hep C) depends on several factors, including the genotype of the virus, the stage of liver disease, any previous treatments the patient has undergone, and the presence of other medical conditions. However, as of my last update, direct-acting antiviral drugs (DAAs) are generally considered the most effective and preferred treatment for Hep C.
Several DAAs are available, and the choice of medication often depends on factors such as genotype, treatment history, and the presence of liver cirrhosis. Some commonly used DAAs include:
Sofosbuvir (Sovaldi)
Ledipasvir-sofosbuvir (Harvoni)
Glecaprevir-pibrentasvir (Mavyret)
Elbasvir-grazoprevir (Zepatier)
Sofosbuvir-velpatasvir (Epclusa)
Sofosbuvir-velpatasvir-voxilaprevir (Vosevi)
These medications are highly effective at suppressing the Hep C virus, often achieving cure rates upwards of 95% across different genotypes. Treatment duration and specific drug combinations may vary depending on individual factors, and it’s crucial for patients to consult with a healthcare provider to determine the most appropriate treatment regimen for their specific situation.
What Are The New Drugs For Hep C?
As of my last update, several newer drugs have been developed for the treatment of Hepatitis C (Hep C), offering improved efficacy, shorter treatment durations, and fewer side effects compared to older therapies. Some of the newer drugs for Hep C include:
Glecaprevir/pibrentasvir (Mavyret): This is a fixed-dose combination medication that can treat all six major genotypes of Hep C. It’s typically taken as a once-daily oral regimen for 8, 12, or 16 weeks, depending on factors such as genotype and prior treatment history.
Sofosbuvir/velpatasvir/voxilaprevir (Vosevi): Vosevi is another fixed-dose combination medication approved for the treatment of chronic Hep C infection in adults with genotypes 1-6. It’s used in patients who have previously failed treatment with other Hep C medications. It’s taken as a once-daily oral regimen for 12 weeks.
Sofosbuvir/velpatasvir (Epclusa): Epclusa is a pan-genotypic fixed-dose combination medication that can treat all six major genotypes of Hep C. It’s typically taken as a once-daily oral regimen for 12 weeks and is approved for use in both treatment-naive and treatment-experienced patients, with or without cirrhosis.
Voxilaprevir (Vosevi): This is a newer protease inhibitor used in combination with other antiviral medications for the treatment of Hep C genotype 1, including patients who have previously failed treatment with DAAs. It’s taken as part of the Sofosbuvir/Velpatasvir/Voxilaprevir regimen (Vosevi).
These newer drugs have significantly advanced Hep C treatment by offering higher cure rates, shorter treatment durations, and improved tolerability compared to older therapies. However, the choice of medication and treatment duration depends on factors such as genotype, prior treatment history, presence of liver cirrhosis, and other individual patient considerations. It’s essential for patients to discuss their treatment options with a healthcare provider to determine the most appropriate regimen for their specific situation.
The old treatment for Hepatitis C (Hep C) primarily involved a combination of pegylated interferon and ribavirin. This treatment regimen was the standard of care for many years before the advent of direct-acting antiviral drugs (DAAs).
Pegylated interferon is a type of interferon that is modified to stay in the body longer, allowing for less frequent dosing. It works by stimulating the body’s immune system to fight the Hep C virus. Ribavirin is an antiviral medication that works by interfering with the replication of the virus.
Treatment with pegylated interferon and ribavirin was often associated with significant side effects, including flu-like symptoms (such as fatigue, fever, and muscle aches), depression, anemia, and other hematologic abnormalities. Additionally, the cure rates with this regimen were lower compared to newer DAAs, and treatment duration could be lengthy, often lasting for 24 to 48 weeks depending on factors such as genotype and treatment response.
Overall, while pegylated interferon and ribavirin represented a significant advancement in Hep C treatment when they were first introduced, they have largely been replaced by newer, more effective, and better-tolerated direct-acting antiviral drugs (DAAs). These newer medications have revolutionized Hep C treatment by offering higher cure rates, shorter treatment durations, and fewer side effects.
Hepatitis C (Hep C) medications can sometimes cause side effects, but they vary from person to person and depend on the specific medication being used.
Older treatments such as pegylated interferon and ribavirin were associated with significant side effects, including flu-like symptoms (such as fatigue, fever, and muscle aches), depression, anemia, and other hematologic abnormalities. These side effects could be quite severe and could impact a person’s quality of life during treatment.
However, the newer direct-acting antiviral drugs (DAAs) used to treat Hep C are generally better tolerated and have fewer side effects compared to older treatments. Common side effects of DAAs may include fatigue, headache, nausea, and occasionally more serious effects such as changes in blood cell counts or liver function tests. However, these side effects are typically milder and less frequent compared to older treatments.
It’s important for individuals undergoing Hep C treatment to communicate any side effects they experience with their healthcare provider. In some cases, adjustments to the treatment regimen or additional supportive care measures may help manage side effects effectively. Overall, while some Hep C medications can cause side effects, the benefits of treatment in curing the infection and preventing liver damage often outweigh the potential risks.
